REGION CHINA

HAN GUISHAN Han has type 2 diabetes China

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company's statutory Annual Report 2018 and Form 20-F, which were both filed with the SEC in February 2019 in continuation of the publication of the Annual Report 2018, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial 'performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

- Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,
- Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
- Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
- Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and regulatory.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this presentation, reference is made to the overview of risk factors in 'Risk management enables better decision-making' on pp 41-43 in the Annual Report 2018.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

Important drug information

- Victoza[®] is approved for the management of type 2 diabetes only
- Saxenda[®] is approved in the USA and the EU for the treatment of obesity only

Note: All notes, sources and abbreviations for this presentation are found in the appendix.






China is the second biggest pharma market globally, with high unmet needs




2_{nd}

Largest pharmaceutical market globally



Sustained solid GDP growth and increasing disposable income



Large unmet needs in diabetes Beijing USD 21,000 GDP per capital 4.6 doctors per patient

Xinjiang USD 7,400 GDP per capital 2.6 doctors per patient

Significant diversity and complexity across provinces





Health is at the centre of government policy, creating a positive environment for sustainable growth

Capitalising on opportunities provided by positive changes in policy and regulatory environment



Responding to challenges by mitigating risks and managing issues as they become certain

Volume-based purchasing
Price erosion (bidding)


- 15 local insulin manufacturers comprising
 - 33% of the market
 - 20+ local biosimilars launches by 2023



Novo Nordisk has a strong presence and a clear strategy * to continue growth and leadership in Region China

Celebrating 25 years of success in Region China ~7 million patients treated in 2019¹

Novo Nordisk Annual sales and share of growth per product group



WIN+2025 strategy to become the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted partner in diabetes, enabling 60 million patients treated by 20251 Image: Comparison of the trusted patients Im


Accelerate innovation



The diabetes market continues its dynamic growth with insulin remaining as the core segment



Region China diabetes market by product class



Product class dynamics highlight opportunities

Insulin



Modern-insulin and new-generation insulin continue to grow



Human insulin challenged by conversion to modern insulin

Modern non-insulin anti-diabetic



Emerging segment, driven by reimbursement and new entrants

Oral anti-diabetic




Price pressures with exposure to volume-based purchasing







Sustaining leadership in insulin is achieved by winning in all three modern and new-generation insulin segments





CAPITAL



Acceleration of the GLP-1 franchise is driven by Victoza[®]

Strong market share and growth with Victoza®




Increasing competition but strong upcoming portfolio and tactics in place

- Increasing GLP-1 competition from new entrants into NRDL
- Dedicated sales organisation to focus on GLP-1



GLP-1 penetration levels across Novo Nordisk regions








Strengthening Biopharm's footprint and building the obesity market is expected to diversify future business



While only representing ~2% of China sales, Biopharm holds strong growth potential



Obesity is a growing problem in China but market development is needed



people with obesity²


Government advocates individuals pay attention to their weight in Healthy China 2030 Action Plan







Novo Nordisk supports building the ecosystem to enable early diagnosis, proper treatment, and better control








The future promises to deliver a more innovative and more diversified portfolio

Novo Nordisk Portfolio



2019 Product Portfolio






The future promises to deliver a more innovative and more diversified portfolio



Novo Nordisk Portfolio

MARKETS





Future Product Portfolio

Closing Remarks

The pharma market in Region China continues to grow and Novo Nordisk is well-positioned to capitalise

Novo Nordisk has a holistic strategy to drive sustainable growth in Region China in the long-term

Novo Nordisk focuses on maximising the portfolio and driving growth in all major segments beyond insulins and beyond diabetes

Novo Nordisk remains a trusted partner, working with stakeholders to change diabetes and other serious chronic diseases



HAN GUISHAN Han has type 2 diabetes China

Sources, Notes and Abbreviations – Region China

- Slide 3: Sources: GDP growth, IMF table for 2019 real GDP projection, <u>https://www.imf.org/external/datamapper/NGDP_RPCH@WEO/OEMDC/ADVEC/WEOWORLD/CHN/DNK;</u> 2018 GDP per capita in USD, National Bureau of Statistics of China. April 1, 2019; the average exchange rate in 2018 is CNY 6.6174 per USD; Doctor per 1000, Regional macro economy data, <u>http://calendar.hexun.com/area/</u>, country summary table (18-99 years), 2017
- Slide 4: ¹Time from CTA submission to approval; source: DXY insight database; ²Currently only 1 data point for biologic import product; ³Opened for oncology products only
- Slide 5: 1 Number for mainland China only; 2 First nine months, 2019; source: Company reported numbers; OAD: Oral anti-diabetic; MI: Modern insulin; NGI: New-generation insulin
- Slide 6: ¹3-year CAGR; ²Year-to-date; Note: Modern non-insulin anti-diabetic (MNIAD) includes GLP-1, DPP-IV, and SGLT-2; source: IQVIA, MAT, Sep 2019, IQVIA covers around 50% of the total Chinese market (hospital data); OAD: Oral anti-diabetic; MNIAD: Modern non-insulin anti-diabetic; HI: Human insulin; MI: Modern insulin; NGI: New-generation insulin
- Slide 7: Source: IQVIA, MAT, Sep 2019; IQVIA covers around 50% of the total Chinese market (hospital data)
- Slide 8: 13-year CAGR; Source: IQVIA, MAT, Sep 2019; IQVIA covers around 50% of the total Chinese market (hospital data)
- Slide 9: ¹ First 9 months, 2019; ² Obesity as defined by Chinese standard = BMI>28; number is for adults only; source: Nutrition and Chronic Diseases of Chinese Resident in 2012 (published in 2015), see also Healthy China Action (2019-2030)
- Slide 11: ¹ Innovative products: Product with a compound or formulation patent; Diversified means products other than insulin
- Slide 12: 1 Innovative products: Product with a compound or formulation patent; Diversified means products other than insulin







APPENDIX

Region China: Diabetes market share and market growth

Diabetes market growth and Novo Nordisk market share



Diabetes market size and growth








Source: IQVIA, September 2019, Value, MAT, all countries

Region China: Insulin market size and volume share of growth and market share








Region China: GLP-1 market share and market growth

GLP-1 market growth and Novo Nordisk market share

160% 101% 120% 93% 80% 82% 40% 53% 0% Sep Sep 2016 2019 - NN market share — Market growth — NN growth

GLP-1 market size and growth





CAPITAL MARKETS DAY

Source: IQVIA, September 2019, Value, MAT, all countries; Share of growth not depicted due to too high numbers